Amylyx Pharmaceuticals, Inc. 8-K

What Happened

• Amylyx Pharmaceuticals, Inc. filed an 8-K reporting the results of its Annual Meeting of Stockholders held on June 4, 2026. Stockholders elected two Class II directors — George Mclean Milne Jr., Ph.D. and Paul Fonteyne — each to a three-year term through the 2029 annual meeting. The meeting also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal year 2026 and approved, on a non‑binding advisory basis, the compensation of the company’s named executive officers. The proxy statement for the meeting was filed April 23, 2026.

Key Details

• Director elections: George M. Milne Jr. — 76,937,972 votes for, 14,108,630 withheld, 11,029,810 broker non‑votes; Paul Fonteyne — 86,275,670 votes for, 4,770,932 withheld, 11,029,810 broker non‑votes.
• Auditor ratification: Deloitte & Touche LLP ratified with 102,036,295 votes for, 34,484 against, 5,633 abstaining (0 broker non‑votes).
• Advisory vote on executive compensation: Approved with 77,534,824 votes for, 13,490,653 against, 21,125 abstaining, and 11,029,810 broker non‑votes.
• No other matters were submitted or voted on at the Annual Meeting.

Why It Matters

• Board continuity and governance: Re-election of two Class II directors maintains the board’s composition and oversight continuity through 2029, which can affect strategic direction and investor confidence.
• Auditor confirmation: Ratification of Deloitte confirms continuity of the company’s external audit relationship for 2026, relevant to financial reporting reliability.
• Compensation vote outcome: The non‑binding approval of named executive officer pay signals majority shareholder support for the company’s compensation approach, though it is advisory and does not change pay directly.